Seminars
EVEXIA meets on a montly basis and occasionally hosts guest seminars to share their experiences in investing. These talks are a great opportunity to learn from and network with professionals. If you'd like to speak with the group, send us an email.
From Academia to Investing: How Evexia Served as a Key Pivot Point In Between
August 2024
Roman Camarda, PhD
Vice President, Novo Holdings
Roman reflected on his path from basic resarch, beginning at the University of Washington, to his current position as a VP at Novo Holdings. He shared how an excitement for basic research drove him to earn a PhD, but how he ultimately decided to leverage a scientific background to guide capital allocation.
From Academia to Corporate Strategy
June 2024
Dan Holohan, PhD
Tessera Therapeutics, Associate Director of Corporate Development
Dan discussed his path from scientific research to the business side of biotech. His seminar reflected on the best opportunities to pursue while in grad school, exploration of consulting as a bridging opportunity, discovery of potential roles within the startup world, and how to chart long-term career paths.
Biotech Investing: History and Reflections
October 2023
Evan Markegard, PhD
Managing Partner at AuGC Partners LLC
Evan, who founded EVEXIA nearly 10 years ago, returned to address BioFund Partners ahead of the funds closure. He reflected on how the fund had changed over the years, from its humble origins with a handful of friends, to a large partnership with over 50 members and $200,000 AUM at its peak. Evan credits much of his success to identifying asymmetric risk-rewards in publicly traded stocks which non-experts might overlook. In particularly, scientists have an advantage over institutional investors when trading low-liquidity microcap stocks with messy data readouts. Use your training to your advantage.
The Business of Biotech: Equity Research and Investing
July 2023
Vishal Sethi
Investment Associate, UCSF Foundation Investment Company
Vishal discussed how biotech equity research firms hire and operate, with an emphasis on entrance strategies for PhD level scientists. He also performed mock due-diligence on Viking Therapeutics to demonstrate useful analytical tools and websites for finding information.